Estrogen Receptor-α Binds p53 Tumor Suppressor Protein Directly and Represses Its Function*

Estrogen receptor-α (ERα) promotes proliferation of breast cancer cells, whereas tumor suppressor protein p53 impedes proliferation of cells with genomic damage. Whether there is a direct link between these two antagonistic pathways has remained unclear. Here we report that ERα binds directly to p53 and represses its function. The activation function-2 (AF-2) domain of ERα and the C-terminal regulatory domain of p53 are necessary for the interaction. Knocking down p53 and ERα by small interfering RNA elicits opposite effects on p53-target gene expression and cell cycle progression. Remarkably, ionizing radiation that causes genomic damage disrupts the interaction between ERα and p53. Ionizing radiation together with ERα knock down results in additive effect on transcription of endogenous p53-target gene p21 (CDKN1) in human breast cancer cells. Our findings reveal a novel mechanism for regulating p53 and suggest that suppressing p53 function is an important component in the proproliferative role of ERα.

[1]  P. Hall,et al.  An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[2]  G. Wahl,et al.  The C-terminal lysines fine-tune P53 stress responses in a mouse model but are not required for stability control or transactivation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[3]  W. Gu,et al.  Functional Analysis of the Roles of Posttranslational Modifications at the p53 C Terminus in Regulating p53 Stability and Activity , 2005, Molecular and Cellular Biology.

[4]  Rachel Schiff,et al.  Estrogen-receptor biology: continuing progress and therapeutic implications. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  A. Howell,et al.  Steroid receptors in human breast cancer , 2004, Trends in Endocrinology & Metabolism.

[6]  D. McDonnell.  The molecular determinants of estrogen receptor pharmacology. , 2004, Maturitas.

[7]  V. Jordan,et al.  The biological role of estrogen receptors α and β in cancer , 2004 .

[8]  S. Angeloni,et al.  Regulation of estrogen receptor- expression by the tumor suppressor gene p53 in MCF-7 cells , 2004 .

[9]  D. Lane,et al.  Turning the key on p53 , 2004, Nature.

[10]  D. Medina.  Breast Cancer , 2004, Clinical Cancer Research.

[11]  Myles Brown,et al.  Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy , 2003, Breast Cancer Research.

[12]  B. Shan,et al.  Induction of p53-dependent Activation of the Human Proliferating Cell Nuclear Antigen Gene in Chromatin by Ionizing Radiation* , 2003, Journal of Biological Chemistry.

[13]  R. Verdun,et al.  p53 functions through stress- and promoter-specific recruitment of transcription initiation components before and after DNA damage. , 2003, Molecular cell.

[14]  Barry Komm,et al.  Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. , 2003, Endocrinology.

[15]  Wafik S El-Deiry,et al.  P53 and radiation responses , 2003, Oncogene.

[16]  J. Gustafsson,et al.  Estrogen signaling: a subtle balance between ER alpha and ER beta. , 2003, Molecular interventions.

[17]  B. Nayak,et al.  Stabilization of p53 and transactivation of its target genes in response to replication blockade , 2002, Oncogene.

[18]  Moshe Oren,et al.  Regulation of p53: intricate loops and delicate balances. , 2002, Biochemical pharmacology.

[19]  Xin Lu,et al.  Live or let die: the cell's response to p53 , 2002, Nature Reviews Cancer.

[20]  S. Safe,et al.  Estrogen up-regulation of p53 gene expression in MCF-7 breast cancer cells is mediated by calmodulin kinase IV-dependent activation of a nuclear factor kappaB/CCAAT-binding transcription factor-1 complex. , 2002, Molecular endocrinology.

[21]  Simak Ali,et al.  Endocrine-responsive breast cancer and strategies for combating resistance , 2002, Nature Reviews Cancer.

[22]  Thierry Soussi,et al.  Assessing TP53 status in human tumours to evaluate clinical outcome , 2001, Nature Reviews Cancer.

[23]  B. O’Malley,et al.  p53 is a potential mediator of pregnancy and hormone-induced resistance to mammary carcinogenesis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[24]  B. Wasylyk,et al.  Ligand-dependent interaction of the glucocorticoid receptor with p53 enhances their degradation by Hdm2. , 2001, Genes & development.

[25]  C. Prives,et al.  The C-terminus of p53: the more you learn the less you know , 2001, Nature Structural Biology.

[26]  S. Nakashima,et al.  MDM2 Enhances the Function of Estrogen Receptor α in Human Breast Cancer Cells , 2001 .

[27]  A. Levine,et al.  Surfing the p53 network , 2000, Nature.

[28]  G. Liu,et al.  Estrogen receptor protects p53 from deactivation by human double minute-2. , 2000, Cancer research.

[29]  J. Manfredi,et al.  Identification of a novel class of genomic DNA-binding sites suggests a mechanism for selectivity in target gene activation by the tumor suppressor protein p53. , 1998, Genes & development.

[30]  E. Moran,et al.  Differential Regulation of p53-dependent and -independent Proliferating Cell Nuclear Antigen Gene Transcription by 12 S E1A Oncoprotein Requires CBP* , 1998, The Journal of Biological Chemistry.

[31]  Winship Herr,et al.  Basal promoter elements as a selective determinant of transcriptional activator function , 1995, Nature.